Aileron Therapeutics Q4 2023 Earnings Report

Aileron Therapeutics EPS Results

• Actual EPS: -$1.54
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Aileron Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Aileron Therapeutics Announcement Details

• Quarter: Q4 2023
• Date: 4/15/2024
• Time: N/A

Aileron Therapeutics (NASDAQ:ALRN), a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.